Creating a new treatment for Head and Neck Squamous Cell Carcinoma using antibody and RNA technology
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
This study is testing a new treatment for advanced head and neck cancer that combines a special antibody with a modified RNA to help fight the cancer more effectively, aiming to improve outcomes for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mirecule, INC. NIH-funded |
| Lab location | 1 site (Gaithersburg, UNITED STATES) |
| Project ID | NIH-11008149 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) by combining an antibody, cetuximab, with a modified RNA molecule that mimics a tumor suppressor. The approach aims to target multiple growth factor receptors that cancer cells use to survive and grow, potentially improving treatment outcomes for patients with advanced disease. By using this antibody-RNA conjugate, the research seeks to enhance the effectiveness of existing therapies and address the limitations of current treatments. Patients may benefit from a more comprehensive attack on the cancer cells, which could lead to better survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with locoregionally advanced Head and Neck Squamous Cell Carcinoma who have limited treatment options.
Not a fit: Patients with early-stage Head and Neck Squamous Cell Carcinoma or those whose cancer is not responsive to EGFR-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced Head and Neck Squamous Cell Carcinoma.
How similar studies have performed: Other research has shown promise in using antibody-RNA conjugates for cancer treatment, indicating that this approach may be viable.
Where this research is happening
Gaithersburg, UNITED STATES
- Mirecule, INC. — Gaithersburg, United States (Active)
Researchers
- Principal investigator: Saleh, Anthony D — Mirecule, INC.
- Study coordinator: Saleh, Anthony D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.